Abstract: The present invention refers to a method for the production of live attenuated bacterial strains, suitable as vaccine candidates, comprising the steps of: A. providing a bacterial strain capable of expressing glutamate racemase and possibly D-amino acid transaminase and comprising a peptidoglycan cell wall, and B. inactivating the gene or genes encoding for the glutamate racemase enzyme and, if needed, the gene or genes encoding for the enzyme D-amino acid transaminase in such way that the bacterial strain is no longer capable of expressing a functional glutamate racemase and/or a functional D-amino acid transaminase; wherein the inactivation of said genes causes said bacterial strain to be auxotrophic for D-glutamate.

Abstract: Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.

Abstract: Disclosed herein is a photochemical preparation method of an autologous plasma inactivated vaccine for the treatment of acquired immune deficiency syndrome (AIDS), including the following steps: drawing autologous blood from an AIDS patient to form blood to be treated; separating the blood to obtain plasma to be treated; adding a photosensitizer into the plasma to be treated to form plasma to be inactivated; and subjecting the plasma to be inactivated to photochemical inactivation to obtain the autologous plasma inactivated vaccine.

Abstract: The invention provides a composition useful to prepare high titer influenza B viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza B virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, that confer enhanced growth in cells in culture, such as MDCK cells, or in eggs.

Abstract: Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified neuraminidases by influenza virus may also stabilize co-expressed hemagglutinins so that the hemagglutinins do not undergo mutation.

Abstract: The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

Abstract: The present invention includes a composition and a method of modulating an immune response with a composition that comprises an anti-BAFF receptor antibody or binding fragment thereof that is bound or conjugated to an siRNA, and shRNA, or both, that targets a BAFF receptor mRNA.

Abstract: The invention features multi-specific protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to a disease antigen, immune checkpoint or signaling molecule.

Abstract: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.

Abstract: The invention provides liquid injectable copolymers of TMC and HTMC that are degradable in vivo. Degradation can be tailored by adjusting the amount of HTMC in the copolymer, the initial molecular weight of the copolymer, and the characteristics of the initiator used in its preparation. Specifically, the degradation rate increases as the amount of HTMC incorporated into the copolymer increases, as the molecular weight of the copolymer decreases, and as the hydrophobicity of the initiator decreases. Moreover, the degradation yields products such as glycerol and carbon dioxide that are non-toxic in vivo, and which will not cause a substantive change in tissue pH upon implantation in vivo. The copolymers may be used in applications such as drug delivery and as coatings.

Abstract: Pharmaceutical compositions comprising two or more therapeutically active agents, such as two or more anticancer agents, conjugated to one or more biocompatible polymers, wherein the molar ratio of the agents and/or schedules of delivery provide a synergistic therapeutic effect, are described. Methods of making and using the pharmaceutical compositions are further described. In one embodiment, the pharmaceutical compositions contain topoisomerase I and topoisomerase II inhibitors conjugated to the same or different biocompatible polymers. The two or more anticancer agents are covalently coupled to the polymer(s), and thereby can be delivered to a tumor at a molar ratio which provides a synergistic effect. Optionally, the agents are coupled indirectly to the polymer(s) via a linker.

Abstract: The invention provides compositions and methods for the treatment or prevention of pain. Compositions provided are resistant to overdose and abuse. Compositions provided comprise two or more different molecules, where each molecule comprises at least one GI enzyme-labile opioid agonist releasing subunit comprising an opioid agonist that is covalently linked to at least one GI enzyme inhibitor subunit.

Abstract: Dual variable domain (DVD) immunoconjugates and uses thereof are provided. Aspects of the subject immunoconjugates include a DVD immunoglobulin molecule having a first and a second variable domain, and a cargo moiety (e.g., a drug moiety) that is covalently conjugated to the second variable domain via a linker. Methods of making and using the subject immunoconjugates in the prevention and/or treatment of cancer and other diseases are also provided.

Abstract: The present invention provides a method for inducing an inversion of normal blood coagulation factor VIII (F8) gene, a method for correcting an inversion of blood coagulation factor VIII gene in which the inversion has occurred, and a Hemophilia A patient-derived induced pluripotent stem cell in which the inversion is corrected, constructed using the same. The method of the present invention effectively reproduces the inversion of intron 1 and intron 22 of the F8 gene, which is responsible for the majority of severe hemophilia A, and thereby may be effectively used for studying the development mechanism of hemophilia A and as a research tool for screening therapeutic agents. The inversion-corrected induced pluripotent stem cell constructed according the method of the present invention enables an efficient and fundamental treatment for hemophilia A by restoring a genotype in which mutation has occurred to a wild type-like state, without limitation via normal gene or protein delivery.

Abstract: Codon optimized nucleic acid sequences for RDH12 are provided, as well as recombinant viral vectors, such as AAV, expression cassettes, proviral plasmids or other plasmids containing the codon optimized sequence for functional RDH12. Recombinant vectors are provided that express the codon optimized, functional RDH12. Compositions containing these codon optimized sequences are useful in methods for treating, retarding or halting certain blinding diseases resulting from the absence, deficiency or inappropriate expression of RDH12. Other compositions and methods are providing for correcting a non-functional, defective or inadequately expressed native RDH12.

Abstract: A recombinant adeno-associated virus (rAAV) having an AAV8 capsid which is suitable for intra-retinal injection is provided herein. The rAAV comprises a vector genome packaged within the capsid which contains, operably linked to regulatory elements which direct expression of anti-human vascular endothelial growth factor (VEGF) antigen binding antibody fragment (aVEGF), a coding sequence for aVEGF, wherein the coding sequence is operably linked to regulatory elements which direct expression of the anti-VEGF Fab in the eye. Also provided herein are liquid suspensions containing these rAAV8.aVEGF and methods of using same for treatment of wet AMD and other ocular conditions.

Abstract: Methods for purifying 89Zr are provided, 89Zr compositions are provided, isotope compositions are provided that can include: a radio isotope and a nanoparticle, and methods for radio labeling monoclonal antibodies are provided.

Abstract: The invention relates to a method for cleaning dissolution vessels and for the subsequent dosing of a dissolution media, and to mobile modular cleaning and dosing equipment for the implementation of said method. According to said method, injected water steam is used for the cleaning and is subsequently aspirated, together with the residues of the dissolution, and the vessel is then refilled with the desired quantity of a new dissolution media. The mobile modular cleaning and dosing equipment allows the cleaning and dosing to be carried out in situ without having to remove the dissolution vessels from the equipment or site where the dissolution tests are carried out, using self-sufficient modular equipment, and a novel steam supply line is used for the cleaning, which sprays the steam against the bottom of the vessel and the inner side walls.

Abstract: The present invention relates to a method and apparatus for preventing bacterial cross-contamination between a user's personal item and a bacterially sensitive environment. More particularly, the present invention is directed to a method and apparatus for sanitizing a user's hands and cell phone prior to the user entering into a sterile operating room, thereby minimizing the introduction of contaminants via the cell phone.

Abstract: An aroma diffuser comprises a host and an aromatherapy nebulizer; the host has an air pump received therein; the air pump has an air inlet port and an air outlet port; the aromatherapy nebulizer comprises a nebulizer cap and an essential oil bottle with a dip tube extending from the nebulizer cap into the essential oil bottle for sucking liquid essential oil up. The host sets a mounting ring extending outwards from a sidewall thereof, the aromatherapy nebulizer is installed in the mounting ring in such way that the aromatherapy nebulizer is able to be plugged in or pulled out up and down through the mounting ring, thereby the aromatherapy nebulizer is installed externally to the host.

Abstract: In some embodiments, a system for purifying an environment may be provided. The system may include a first electrode which may be exposed to air. The system may include a first transducer which may be configured to apply a first energy to the first electrode and a second transducer which may be configured to apply a second energy to the first electrode. The system may be configured such that at a first time, the first transducer applies the first energy to the first electrode and the second transducer does not apply the second energy to the first electrode. The system may be further configured such that at a second time, the second transducer applies the second energy to the first electrode.

Abstract: A fan is for improving air quality, such as in an indoor environment. The fan includes a motor and a rotatable hub coupled to the motor. At least one fan blade includes a first end portion coupled to the rotatable hub and a second end portion radially distant from the rotatable hub. At least one ion generator is carried by the second end portion of the at least one fan blade, such as by a winglet associated therewith. A stationary tube passes through the rotatable hub including a conduit for transmitting power. A rotary coupling is also provided for transmitting power from the conduit to the at least one ion generator.

Abstract: The present invention provides methods and compositions for promoting regeneration of a tissue, methods for preventing or reducing inflammation of a tissue, methods for preventing or reducing fibrosis of a tissue, methods for increasing a mass of a tissue, methods for increasing a level of oxygen available to a tissue, methods for increasing a rate of metabolic waste removal from a tissue, methods for increasing blood perfusion to a tissue, and methods of treating severe muscle tissue damage in a subject in need thereof by contacting the tissue with a composition that is suitable for applying cyclic mechanical compression to the tissue.

Abstract: Described herein are bioengineered constructs and methods of producing the same. The constructs and methods disclosed herein can be applied towards, for example, the generation of vascular grafts to treat cardiovascular disease.

Abstract: Described herein are methods and apparatus for constructing tissue replacements, such as bone replacements that may be used to repair damaged or missing segments of bone, such as may occur in wound repair or as a repair of a congenital anomaly. These methods involve a three-dimensional (3D) cell growth medium made from a yield stress material that allows cells and structures to be easily deposited and positioned.

Abstract: This invention relates to microgel compositions, and in particular, to gel compositions fanned by binding a plurality of individual microgel particles together. The present invention also relates to processes for the preparation of these compositions and their use for particular applications, especially medical applications such as the repair of damaged, degenerated or inappropriately formed load-beating tissue (such as, for example, intervertebral discs).

Abstract: This invention relates to thermoresponsive hydrogels. Particularly, the invention relates to a thermoresponsive hydrogel comprising copolymer polyethylene glycol (PEG)-polycaprolactone (PCL)-polyethylene glycol (PEG) and polypropylene fumerate (PPF). The thermoresponsive hydrogel may further comprise a poloxamer, particularly Pluronic F-127. The invention extends to a method of manufacturing thermoresponsive hydrogels, also extends to an ink for a three dimensional (3D) printer including the thermoresponsive hydrogels. The invention further extends to a thermoresponsive hydrogel for use in the treatment of a bone injury and/or a bone defect, and/or to a method of treating a bone injury and/or a bone defect. The thermoresponsive hydrogels may include dispersed therein an active pharmaceutical ingredient (API), preferably an API falling in the Biopharmaceutics Classification System (BCS) class II, further preferably a statin type drug, most preferably simvastatin.

Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

Abstract: Absorbable barrier composites are designed for modulated gas and water permeability depending on clinical use and are formed of at least two physicochemically distinct components, one of which is a film adjoined to a knitted mesh and/or electrostatically spun, non-woven fabric. Depending on the physicochemical properties of the barrier composite, it can be used in neurological and urinogenital surgical procedures as well as tissue engineering and/or as physical barriers to prevent adhesion formation following several types of surgical procedures.

Abstract: An apparatus and method are disclosed for detecting the disconnection of a vascular access device such as a needle, cannula or catheter from a blood vessel or vascular graft segment. A pair of electrodes is placed in direct contact with fluid or blood in fluid communication with the vascular segment. In one embodiment, the electrodes are incorporated into a pair of connectors connecting arterial and venous catheters to arterial and venous tubes leading to and from an extracorporeal blood flow apparatus. Wires leading from the electrodes to a detecting circuit can be incorporated into a pair of double lumen arterial and venous tubes connecting the blood flow apparatus to the blood vessel or vascular graft. The detecting circuit is configured to provide a low-voltage alternating current signal to the electrodes to measure the electrical resistance between the electrodes, minimizing both the duration and amount of current being delivered.

Abstract: A vascular access port can include a base that can be attached to a vessel and a body extending away from the base in at least a vertical direction. A height of the body in the vertical direction can be sufficiently small such that the entire port can be implanted subcutaneously in a patient. The port can include a guidance passageway that is at least partially defined by the body and can direct an access device into a vessel of a patient when the port is attached to the vessel. In some arrangements, the guidance passageway includes a funnel region that decreases in size from a proximal end of the guidance passageway toward a distal end of the guidance passageway that defines an opening through the bottom surface of the port.

Abstract: The present invention provides an apparatus comprising a wound dressing connected to a fluid container via a pump, wherein the wound dressing is in communication with a mechanical pressure control valve, the fluid container is provided with an inlet and an outlet. Also provided are (i) flexible fluid containers comprising of at least two layers of film with an integrated vent, (ii) wound dressings and (iii) a multi-compartment wound fluid container comprising at least two internal compartments and provided with an outlet and an inlet, in which the container comprises a microporous fluid separator which divides the at least two internal compartments, wherein the microporous fluid separator permits gas flow between the compartments and prevents fluid flow to the outlet of the container. Other apparatus provided comprises a means for detecting the level of fluid within a multi-compartment wound fluid container as described.

Abstract: A drive mechanism for an insertion mechanism for an administering device, having a base and a guide track. A slider of the drive mechanism provided on the base in a rotationally fixed manner can be slid along or in the guide track between end positions. A drive wheel is rotatably mounted on the base. A drive track is connected to the slider and has a plurality of drive sections, and an energy source, by means of which the drive wheel can be set into rotation. Upon rotation of the drive wheel, the slider moves along the guide track in the distal direction to a distal end of the guide track and slider is moved along or in the guide track in the proximal direction. The energy source can be coupled to the drive wheel by means of a one-piece or multi-piece transmission element and of an introduction wheel.

Abstract: A model-based control scheme consisting of either a proportional-integral-derivative (IMC-PID) controller or a model predictive controller (MPC), with an insulin feedback (IFB) scheme personalized based on a priori subject characteristics and comprising a lower order control-relevant model to obtain PID or MPC controller for artificial pancreas (AP) applications.

Abstract: Embodiments include methods and systems for maintaining glucose homeostasis. Systems can include a pump, a first reservoir including a homeostasis agent, an umbilical catheter capable of being advanced in the umbilical vein or in the falciform ligament, and a sensor. Systems can also include a biocompatible coating, a microprocessor in communication with the pump and the sensor, and a power supply. Methods can include implanting a pump and reservoir subcutaneously in a patient, advancing a catheter in the umbilical vein or in the falciform ligament, measuring a blood glucose level, pumping a homeostasis agent, and administering the homeostasis agent to the portal venous system.

Abstract: A drug delivery device comprising a rotatable scale drum, a trigger member, an actuation member, a trigger spring acting on the trigger member and being energized by movement of the actuation member, as well as an end-of-dose switch adapted to be actuated by movement of the trigger member. The trigger member is adapted to be arranged in an axially supported position against the action of the energized trigger spring, and released from the axially supported position when the scale drum is rotated from a set position to an end-of-dose position, whereby the trigger member is moved axially by the trigger spring, the end-of-dose switch thereby being actuated.

Abstract: An auto-injector for administering a dose of a liquid medicament includes an elongate housing arranged to contain a syringe with a hollow needle and a stopper for sealing the syringe and displacing the medicament, the housing having a distal end and a proximal end with an orifice intended to be applied against an injection site. The syringe is slidably arranged with respect to the housing. A spring capable of, upon activation: pushing the needle from a covered position inside the housing into an advanced position through the orifice and past the proximal end (P), operating the syringe to supply the dose of medicament (M), and retracting the syringe with the needle into the covered position. After delivering the medicament, an activator arranged to lock the spring in a pressurized state prior to manual operation and capable of, upon manual operation, releasing the spring for injection.

Abstract: A drive mechanism suitable for use in drug delivery devices is disclosed. The drive mechanism may be used with injector-type drug delivery devices, such as those permitting a user to set the delivery dose. The drive mechanism may include a housing, a dose dial sleeve, and a drive sleeve. A clutch is configured to permit rotation of the drive sleeve and the dose dial sleeve with respect to the housing when the dose dial sleeve and drive sleeve are coupled through the clutch. Conversely, when the dose dial sleeve and drive sleeve are in a de-coupled state, rotation of the dose dial sleeve with respect to the housing is permitted and rotation of the drive sleeve with respect to the housing is prevented. In the de-coupled state, axial movement of the drive sleeve transfers force in a longitudinal direction for actuation of a drug delivery device.

Abstract: The present invention relates to a filtering syringe, and more particularly, to an apparatus obtained by improving a syringe provided with a filter means for filtering foreign substances such as glass fragments of an ampoule, so as to prevent the foreign substances from being injected together with a liquid medicine while allowing the liquid medicine to be smoothly sucked and injected with a small force, especially even though a filter means having micro-pores is employed. The filtering syringe is configured such that the filter means is provided in the injection flow passage to prevent the foreign substances from being injected together with the liquid medicine while enabling the liquid medicine to be more smoothly sucked and injected despite employing the filter means having the micro-pores, thereby maximizing user's convenience and marketability of the syringe.

Abstract: Flush syringe assemblies capable of creating pulsatile movement of the plunger rod as it moves in the distal direction within a syringe barrel, while preventing overpressurization of the catheter are provided. An exemplary flush syringe assembly includes a syringe barrel with a first pulsing element and a chamber with flush solution, a plunger rod with a stopper and a second pulsing element that interacts with the first pulsing element to provide an engagement force that causes pulsatile movement of the plunger rod and a thumb press slidably attached to the plunger rod with a pulse control element. The pulse control element is compressible to create a compression force that is greater than the engagement force of the first pulsing element and the second pulsing element.

Abstract: A plunger head to measure fluid in a drug cartridge includes a transducer coupled to emit ultrasonic signals, and a power source. A controller is coupled to the transducer and the power source, and the controller includes logic that when executed by the controller causes the plunger head to perform operations. For example the plunger head may emit the ultrasonic signals along a length of the drug cartridge, when the plunger head is disposed in the drug cartridge, and receive the ultrasonic signals after the ultrasonic signals are reflected from a dispensing end of the drug cartridge. The plunger head may then determine when the ultrasonic signals received by the transducer have an absolute value of amplitude greater than a first threshold value, and associate a timestamp with the ultrasonic signals received that have the absolute value of amplitude greater than the first threshold value.

Abstract: A supplementary device is configured to be attached to a drug delivery device. The supplementary device comprises a non-contact sensor configured to output signals indicative of the position of a moveable component within the drug delivery device. The supplementary device further comprises a processor configured to receive the signals output from the non-contact sensor. This processor is additionally configured to determine, based on the signals, whether the drug delivery device is in a pre-activation state or a post-activation state.

Abstract: One or more embodiments of the disclosure relate, generally, to a replacement pen cap for a medication injection pen comprising at least one temperature sensor for monitoring a temperature of a medication, detect dosing events, and determine that medication may be denatured based on temperature data, received analyte measurement data prior, and the detected dosing events.

Abstract: The system allows optimizing the dispensing of aerosol medicaments. In particular the system allows the administration of an exogenous pulmonary surfactant to very young patients (e.g. preterm neonates). A catheter (101) conveys atomized surfactant directly to the retropharyngeal region in order to increase efficiency of the medicament administration without being invasive: this is particularly important for very young patients, such as pre-term born neonates suffering from neonatal Respiratory Distress Syndrome (nRDS). The catheter is made of biocompatible flexible material (e.g. plastic material). It is possible to couple the catheter with a rigid scaffolding (e.g. metallic) to increase stiffness of the device and to improve easiness of positioning operations. The delivery of the atomized medicament is done by means of an air blasting technique.

Abstract: An electronic vaping device is provided including a power supply portion comprising a power supply, an atomizer/liquid reservoir portion comprising a liquid reservoir storing a liquid, and an atomizer adapted to atomize the liquid stored in the liquid reservoir when operated by the power supply. The atomizer is adapted to float on the surface of the liquid in the liquid reservoir.

Abstract: This invention relates to apparatus used to alter the temperature and humidity of gases. The apparatus of the present invention comprises an insufflator, humidifier and transportation means connected to delivery means to deliver humidified and heated gases to a body cavity prior to and during a medical procedure. In one form of the present invention the insufflator and humidifier are contained in the one housing, while in another form the humidifier is located proximal and external to the insufflator. The transportation means that delivers the humidified gases to the body cavity comprises a flexible tubing having located within, throughout or around it heating means. The heating means may be a heat conductive wire, a ribbon of PTC material, or a conducting wire extruded into the walls of tubing, where the tubing may be made from a PTC material or flexible plastics.

Abstract: A system for performing an endoscopic surgical procedure in a surgical cavity of a patient that includes a gas delivery device configured to deliver a flow of pressurized gas to a gas delivery lumen extending therefrom, a gaseous sealing module communicating with a distal end of the gas delivery lumen and configured to generate a gaseous seal within a gas sealed lumen extending therefrom, and an access port communicating with a distal end of the gas sealed lumen so as to provide sealed instrument access to the surgical cavity and maintain a stable pressure within the surgical cavity.

Abstract: The present invention is directed to an assembly and method of use thereof for reducing microbial load in an airway of a patient. The assembly includes a miniature vacuum unit. The miniature vacuum unit includes a housing, at least one air inlet configured in the housing for air intake; a vacuum motor for sucking the air through the at least one air inlet; vents configured in the housing for blowing the sucked air out of the housing, a filter media covering inner side of the vents, such as the sucked air passes through the filter media, the filter media configured to retain microbes suspended in the sucked air; and at least one suction tube. The suction tube is having a proximal end and a distal end, the proximal end of the at least one suction tube configured to sealably and releasably coupled to the at least one air inlet, a plurality of apertures configured in the wall of the suction tube near its distal end. The suction tube configured to be positioned within the mouth of the patient.

Abstract: A flow generator (21) for a respiratory therapy system configured to deliver a breathable gas flow to a patient comprises a housing (27) comprising an inlet (28) and an outlet (25) and a gas flow path between the inlet (28) and outlet (25). An impeller is mounted within the housing (27) for rotation about an axis, the impeller configured to be rotationally driven by a motor to provide a gas flow along the gas flow path. Various embodiments are disclosed in which the flow generator (21) further comprises a sensor (23) mounted in the housing (27) in the gas flow path and configured to detect a property of the gas flow. The sensor (23) may be mounted in the outlet (25) so as to project into the gas flow path. Flow generator may comprise an axial inlet (28) and a tangential outlet (25). In another embodiment the sensor (23) may be mounted in the inlet (28).

Abstract: A humidifier uses a field of hydrophobic, nanotubes (e.g., vertically aligned carbon nanotubes) to humidify a gas. Voids in the field form liquid flow channels that are wide enough for liquid water to pass through. The nanotubes are spaced close enough to each other to prevent the water from escaping the channels. Water in the channels is absorbed by gas that flows and/or diffuses between the nanotubes. Humidity levels in the gas can be measured and controlled to a desired level by controlling the rate of flow of gas through the humidifier, controlling heating of the gas, and/or adjusting the total area of molecular transfer from the water to the gas by providing multiple banks of nanotubes and controlling the number of banks through which the gas flows.